AbGn-168H is under clinical development by AltruBio and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AbGn-168H’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AbGn-168H overview
AbGn-168H (neihulizumab) is under development for the treatment of moderate to severe chronic plaque psoriasis, steroid-refractory acute graft versus host disease (GVHD) and psoriatic arthritis (PsA). The drug candidate is administered as an intravenous infusion. It is a monoclonal antibody that acts by targeting CD162 antigen. It was also under development for plaque psoriasis as a subcutaneous or intravenous infusion, renal transplantation, type 1 diabetes and ulcerative colitis.
AltruBio overview
AltruBio is a clinical-stage biopharmaceutical company developing immune modulating drugs for inflammatory and autoimmune diseases. Its pipeline products include ALTB-168 for the treatment of ulcer, arthritis, graft versus host disease and psoriasis which acts by down regulating activated T cells and enhances PSGL-1’s natural immune function. The company’s pipeline product ALTB-268 used for the treatment of ulcerative colitis and solid organ transplantation. It operates through offices in the US and Taiwan. AltruBio is headquartered in Redwood, California, the US.
For a complete picture of AbGn-168H’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
